Corporate Overview

Biosceptre has identified nf-P2X7, a receptor present on the cell surface of many cancer cells and importantly not found on the surface of cells from healthy tissue. Our evidence suggests that drugs directed to nf-P2X7 have the potential to treat multiple cancers. Biosceptre is conducting clinical trials to generate data that will underpin the potential of the technology. Concurrently Biosceptre is developing diagnostic approaches that can detect and monitor cancer.